Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer.
Journal: JCO precision oncology
Published: July 30, 2020
Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 03, 2020
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.
Journal: Clinical lung cancer
Published: February 12, 2020
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 24, 2018
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 16, 2018
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 19, 2017
Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 15, 2017
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 23, 2017
Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.
Journal: Cancer treatment communications
Published: January 24, 2017
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 21, 2016
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 15, 2016
Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma.
Journal: Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
Published: June 02, 2016
Last Updated: 09/26/2026